Top 10 ASX Dividend Stocks for Nov 2026 Download Free Report

1800-272-662
Shopping Cart 0
countryflagAU
Login

Home CompaniesOrthocell Ltd

Orthocell Ltd

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
0.575 AUD -0.01 ( 0.86%)
Last update at 2026-11-12T05:10:00Z
VOLUME
214161
Market Cap
151.18M

Momentum Score

…

Orthocell Limited, a regenerative medicine company, develops and commercializes cell therapies and biological medical devices for the repair of various bone and soft tissue injuries in Australia and internationally. It offers Ortho Autologous Chondrocyte Implantation, a cartilage cell therapy for treatment of articular cartilage defects in the knee and ankle; OrthoATI, for treatment of chronic tendon injuries; Striate+, a resorbable collagen membrane used for guided bone and tissue regeneration in dental applications; and Remplir, a collagen scaffold used in peripheral nerve repair. The company also develops Collagen Medical Device platform products for bone, nerve, tendon, muscle, or scar tissue, and ligament repair; and Tendon Cell Therapy for rotator cuff and lateral epicondyle indications. Orthocell Limited was incorporated in 2006 and is headquartered in Murdoch, Australia.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.57
Low
0.60
High
52 Week Price Range
0.49
Low
1.16
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Orthocell Ltd is an Australian regenerative medicine company focused on collagen-based scaffolds and autologous cell therapies for dental and musculoskeletal repair, with CelGro as its lead commercial product. Long-term growth may be driven by wider clinical adoption, regulatory approvals, geographic expansion and successful pipeline progression, which could make it attractive to investors seeking exposure to tissue-regeneration technologies.

Material risks include limited commercial scale and revenues, reliance on regulatory and clinical outcomes, manufacturing and execution challenges, competition and the need for additional financing.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
0.58
Dividend Yield
-
Revenue TTM
11.41M
Revenue Per Share
0.04
Gross Profit TTM
6.69M
Debt / Equity
0.05
ROE
-56.82%
Net Debt
-7.90M
ROCE
-39.56%
Diluted EPS TTM
-0.05

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Type yearly yearly yearly yearly yearly
Date 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Income before tax -13.91M -11.75M -10.23M -9.41M -11.25M
Net income -13.91M -8.57M -7.18M -6.25M -9.11M
Selling general administrative 26.77M 3.95M 3.61M 4.25M 2.24M
Selling and marketing expenses - 5.46M 3.09M 1.71M 3.30M
Gross profit 3.68M 4.80M 3.69M 3.22M 0.83M
Reconciled depreciation 0.72M 0.55M 0.52M 0.55M 0.35M
Ebit -18.38M -13.98M -12.20M -10.89M -11.87M
Ebitda -17.52M -13.43M -11.68M -10.34M -11.52M
Depreciation and amortization 0.86M 0.55M 0.52M 0.55M 0.35M
Operating income -18.38M -13.98M -11.68M -10.28M -11.52M
Other operating expenses 29.79M 21.53M 17.00M 14.50M 12.87M
Interest expense - - 0.06M - 0.08M
Tax provision 0.00M -3.19M -3.05M -3.16M -2.14M
Interest income 1.82M 1.30M 1.03M 0.85M 0.08M
Net interest income 1.82M 1.25M 0.97M 0.85M 0.08M
Income tax expense - -3.19M -3.05M -3.16M -2.14M
Total revenue 11.41M 7.55M 5.32M 4.24M 1.53M
Total operating expenses 22.06M 18.78M 15.37M 14.11M 12.70M
Cost of revenue 7.73M 2.75M 1.63M 1.03M 0.70M
Total other income expense net 4.47M 2.22M 1.45M 0.08M 0.19M
Net income from continuing ops -13.91M -8.57M -7.18M -6.25M -9.11M
Net income applicable to common shares - -8.57M -7.18M -6.25M -9.11M
Breakdown 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Type yearly yearly yearly yearly yearly
Date 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Total assets 54.81M 35.24M 26.62M 29.61M 37.90M
Intangible assets 0.77M 1.07M 1.05M 1.13M 1.23M
Other current assets 1.11M 0.20M 0.01M 0.17M 0.08M
Total liab 20.40M 20.67M 22.08M 23.46M 27.99M
Total stockholder equity 34.41M 14.57M 4.53M 6.15M 9.90M
Other current liab 3.09M 2.08M 1.50M 1.17M 2.63M
Common stock 114.75M 83.49M 62.22M 57.90M 57.48M
Capital stock 114.75M 83.49M 62.22M 57.90M 57.48M
Retained earnings -87.94M -74.07M -65.63M -59.08M -53.49M
Other liab - - - 18.54M 20.79M
Cash 9.45M 28.62M 20.61M 24.82M 11.02M
Cash and equivalents - - - 24.82M 11.02M
Total current liabilities 8.34M 6.40M 5.31M 4.53M 6.82M
Current deferred revenue 2.31M 2.30M 2.30M 2.30M 0.78M
Net debt -7.90M -28.04M -19.92M -24.26M -10.51M
Short term debt 0.98M 0.33M 0.15M 0.18M 0.12M
Short long term debt total 1.55M 0.58M 0.69M 0.56M 0.51M
Other stockholder equity - - - -1.89M -7.07M
Property plant equipment - - - 1.61M 1.40M
Total current assets 49.80M 31.83M 23.01M 26.87M 35.26M
Long term investments 0.91M - - - -
Net tangible assets - - - 5.02M 8.67M
Short term investments 34.70M - - - -
Net receivables 2.85M 1.81M 1.21M 0.84M 23.55M
Inventory 1.69M 1.20M 1.18M 1.03M 0.61M
Accounts payable 1.96M 1.69M 1.35M 0.88M 3.28M
Accumulated other comprehensive income 7.59M 5.15M 7.94M 7.34M 5.91M
Non currrent assets other - - 1.05M -2.74M -2.63M
Non current assets total 5.00M 3.40M 3.61M 2.74M 2.63M
Capital lease obligations 0.97M 0.58M 0.69M 0.56M 0.51M
Long term debt total - - - 0.38M 0.39M
Breakdown 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Type yearly yearly yearly yearly yearly
Date 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Investments -35.70M -0.36M -0.94M -0.63M -0.54M
Change to liabilities - - - -2.98M 25.27M
Total cashflows from investing activities -36.97M -0.36M -0.94M -0.63M -0.54M
Net borrowings - - - -0.16M -0.15M
Total cash from financing activities 31.12M 17.05M 3.24M -0.16M 1.49M
Change to operating activities - - - 0.22M 0.10M
Net income -13.91M -8.57M -7.18M -6.25M -9.11M
Change in cash -19.17M 8.01M -4.20M 13.80M -5.31M
Begin period cash flow 28.62M 20.61M 24.82M 11.02M 16.33M
End period cash flow 9.45M 28.62M 20.61M 24.82M 11.02M
Total cash from operating activities -13.32M -8.68M -6.51M 14.59M -6.26M
Issuance of capital stock 31.80M - - - 1.64M
Depreciation 0.86M - 0.52M 0.55M 0.35M
Other cashflows from investing activities - -0.10M -0.02M - -
Change to inventory -0.49M -0.07M -0.17M -0.44M -0.15M
Change to account receivables -1.01M -0.52M -0.32M 20.95M -23.25M
Sale purchase of stock -1.59M -0.88M -0.12M - 1.64M
Other cashflows from financing activities -0.24M 17.93M 3.24M -0.16M -0.15M
Change to netincome - - - 2.54M 0.52M
Capital expenditures 1.11M 0.36M 0.94M 0.63M 0.54M
Change in working capital -3.88M -2.30M -1.94M 20.51M -23.40M
Stock based compensation - - 2.10M 2.49M 0.50M
Other non cash items 3.61M -6.38M 2.10M 20.29M 2.50M
Free cash flow -14.43M -9.04M -7.45M 13.96M -6.80M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(AUD)
Price
(AUD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
OCC
Orthocell Ltd		 -0.01
0.86%		 0.57 - - 13.25 4.28 9.13 -3.88
CSL
CSL Ltd		 2.86
1.42%		 204.54 - 22.57 6.15 4.48 4.82 10.06
TLX
TELIX Pharmaceuticals Ltd		 -0.32
2.28%		 13.70 93.87 166.67 5.37 6.37 3.85 47.29
NEU
Neuren Pharmaceuticals Ltd		 -0.30
1.25%		 23.66 154.93 36.36 42.38 7.52 31.95 160.40
MSB
Mesoblast Ltd		 -0.07
3.69%		 1.96 - 454.55 23.43 3.36 18.28 -9.86

Profile*

Orthocell Ltd

Orthocell Limited, a regenerative medicine company, develops and commercializes cell therapies and biological medical devices for the repair of various bone and soft tissue injuries in Australia and internationally. It offers Ortho Autologous Chondrocyte Implantation, a cartilage cell therapy for treatment of articular cartilage defects in the knee and ankle; OrthoATI, for treatment of chronic tendon injuries; Striate+, a resorbable collagen membrane used for guided bone and tissue regeneration in dental applications; and Remplir, a collagen scaffold used in peripheral nerve repair. The company also develops Collagen Medical Device platform products for bone, nerve, tendon, muscle, or scar tissue, and ligament repair; and Tendon Cell Therapy for rotator cuff and lateral epicondyle indications. Orthocell Limited was incorporated in 2006 and is headquartered in Murdoch, Australia.

161 Campus Drive, Murdoch, WA, Australia, 6150

61 8 9360 2888

https://orthocell.com

Name Title Year Born
Dr. Stewart James Washer B.Sc., BSc (Hons), Ph.D. Exec. Chairman 1970
Mr. Paul Frederick Anderson CEO, MD & Exec. Director 1966
Ms. Leslie Wise J.D. Exec. Director NA
Ms. Nicole Jane Telford Chief Financial Officer NA
Mr. Alex McHenry Chief Operating Officer NA
Prof. Ming Hao Zheng Chief Scientific Officer and Member of Medical & Scientific Advisory Board NA
Mr. Simon Lee Robertson B.Bus, C.A., CA, M Appl. Fin. Company Sec. 1960
Mr. Paul Frederick Anderson CEO, MD & Executive Director 1966
Mr. Tony Macintyre Chief Manufacturing Officer NA
Mr. Peter Gordon Webse B.Bus, FCIS, FCPA, FGIA, M.A.I.C.D. Company Secretary 1963

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

CU6
AUD 2.05
+23.49%
DMP
AUD 25.06
+12.93%
G6M
AUD 2.74
+10.93%
XRO
AUD 75.17
+6.08%
SGR
AUD 0.17
+6.06%
AXQ
AUD 3.07
-18.35%
BOE
AUD 1.50
-9.39%
GQG
AUD 0.71
-8.97%
MI6
AUD 0.81
-8.52%
ELV
AUD 3.73
-8.35%

Equity Sectors*

  • Basic Materials

    -3.09%

  • Communication Services

    +0.75%

  • Consumer Cyclical

    +0.43%

  • Consumer Defensive

    +0.12%

  • Energy

    -1.07%

  • Financial Services

    -0.02%

  • Healthcare

    +1.08%

  • Industrials

    -0.22%

  • Real Estate

    +0.61%

  • Technology

    -1.69%

  • Utilities

    -0.18%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…